Wellbeing Digital Sciences

Wellbeing Digital Sciences Inc. is a mental healthcare firm dedicated to the creation and implementation of cutting-edge clinical treatment options, such as psychedelic therapy and digital therapeutics, based on clinical research.

Wellbeing Digital Sciences' goal is to use digital technology in healthcare to improve patient experience, physician satisfaction, and outcomes. A network of North American clinics that provide forward-thinking psychedelic therapies and other types of treatment to patients, as well as a contract research organization that provides clinical trials services to clients looking for drug development support the foundation of the company's mission.

Psychedelic News

Wellbeing’s KGK Science Enters Phase II Clinical Trial Research Contract With Halucenex

Evidence-based mental healthcare company Wellbeing Digital Sciences Inc. (NEO: MEDI) (OTC: KONEF) (FRA: SQ2) announced that its wholly-owned subsidiary KGK Science Inc. has entered into

July 22, 2022

Wellbeing Digital Sciences

Wellbeing’s KGK Science Enters Phase II Clinical Trial Research Contract With Halucenex

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use

atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial

Suggestions

Wellbeing Digital Sciences

Wellbeing’s KGK Science Enters Phase II Clinical Trial Research Contract With Halucenex

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use

atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial